Biotheranostics discovers and develops proprietary molecular-based tests that provide physicians with actionable information to help guide cancer treatment.
Location: United States, California, San Diego
Employees: 51-200
Total raised: $32M
Founded date: 2004
Investors 2
| Date | Name | Website |
| - | MVM Partne... | mvm.com |
| - | Evidity He... | evidity.co... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 21.01.2016 | - | $32M | - |
Mentions in press and media 6
| Date | Title | Description |
| 25.06.2026 | Eckuity Capital Launches Fund II and Backs Automata Technologies | Eckuity Capital, a North American healthcare growth equity firm, today announced the first close of Eckuity Capital Fund II and the fund’s inaugural investment, leading the Series C of Automata Technologies alongside Danaher, a global scien... |
| 21.01.2016 | bioTheranostics Raises $32M | bioTheranostics, a San Diego, CA-based developer of molecular diagnostics for cancer, closed a $32m private equity financing. The round was led by MVM Life Science Partners, with participation from Canepa Advanced Healthcare Fund and Health... |
| 21.01.2016 | BioTheranostics Raises $32M | SAN DIEGO, CA, bioTheranostics today announced that it has closed a $32 million financing led by MVM Life Science Partners, with participation of Canepa Advanced Healthcare Fund and HealthQuest Capital. >> Click here for more fundi... |
| 21.01.2016 | bioTheranostics Gets $32M For Cancer Diagnostics | San Diego-based bioTheranostics announced this morning that it has raised $32M in a funding round, and a spinout from parent company bioMerieux. The molecular diagnostics company said the funding was led by MVM Life Science Partners, and al... |
| 21.01.2016 | Cancer diagnostics company bioTheranostics raises $32 Million, announces spin out from bioMérieux | bioTheranostics has developed the diagnostic tests Breast Cancer Index (BCI) and CancerTYPE ID. BCI is a biomarker test that looks for predictive results for the likelihood of benefit from extended endocrine therapy and offers prognostic re... |
| - | Cancer diagnostics company bioTheranostics raises $32 Million, announces spin out from bioMérieux | bioThernostics, a commercial-stage molecular diagnostics company that provides diagnostic, prognostic and predictive tests to support physicians in the treatment of cancer patients, has announced that it closed a $32 million financing round... |